Abstract
Long-read HiFi genome sequencing (GS) allows for accurate detection and direct phasing of single nucleotide variants (SNV), indels, and structural variants (SV). Recent algorithmic development enables simultaneous detection of CpG methylation (mCpG) for analysis of regulatory element (RE) activity directly in HiFi-GS. We generated a comprehensive haplotype-resolved HiFi-GS dataset from a rare disease cohort of 276 samples in 152 families to identify rare (∼0.5%) hyper-mCpG events. We found that 80% of these events are allele-specific and predicted to cause loss of RE (LRE). We demonstrated heritability of extreme hyper-mCpG including rare cis SNVs and SVs causing short (∼200bp) and large hyper-mCpG events (>1 kb), respectively. We identified novel repeat expansions in proximal promoters predicting allelic gene silencing via hyper-mCpG and demonstrated allelic transcriptional events downstream. On average 30-40 LREs overlapped rare disease genes per patient, providing indications for variation prioritization. LRE led to a previously undiagnosed pathogenic allele in DIP2B causing global developmental delay. We propose that use of HiFi-GS in unsolved rare disease cases will allow detection of unconventional diseases alleles due to LRE.
Competing Interest Statement
William J Rowell, Richard Hall, Christopher T Saunders, Daniel Portik, and Aaron M Wenger are current or past employees of Pacific Biosciences
Funding Statement
This work was made possible by the generous gifts to Children's Mercy Research Institute and Genomic Answers for Kids program at Children's Mercy Kansas City.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board (IRB) of Children's Mercy Kansas City gave ethical approval for this work (Study#11120514).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Supplemental files updated Main figures revised Article format reformatted
Data Availability
All data produced in the present study are available upon request via dbGAP using accession number phs002206.v4.p1
